Linsen, F.
Broeder, C.
Sep, M. S. C.
Verhoeven, J. E.
Bet, P. M.
Penninx, B. W. J. H.
Meijer, O. C.
Vinkers, C. H.
Funding for this research was provided by:
Hersenstichting (DR-2019-00290, DR-2019-00290, DR-2019-00290, DR-2019-00290, DR-2019-00290, DR-2019-00290, DR-2019-00290, DR-2019-00290)
Article History
Received: 21 March 2023
Accepted: 29 April 2023
First Online: 11 May 2023
Declarations
:
: This study is conducted according to the principles of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and in accordance with the Medical Research Involving Human Subjects Act (WMO), the General Data Protection Regulation (GDPR) and the Dutch Medical Treatment Contracts Act Wet (WGBO). The RESET-medication study was approved by the MREC Amsterdam UMC, location VUmc (15–10-2021, registration number 2021.0019-NL74549.029.20). All participants give written informed consent prior to the baseline assessment. When participating in the fMRI sub-study, a separate written informed consent is given.
: Not applicable.
: Author OCM declares receiving funding from Corcept Therapeutics, not related to this project. All other authors declare that they have no competing interests. Study medication is made available by Corcept Therapeutics, Inc (TSB, JB), Menlo Park. The study is an investigator-initiated study with the Amsterdam UMC, location VUmc as study sponsor. The study funders or Corcept Therapeutics had no role in the design of the study, the collection, analysis and interpretation of the data, or in the preparation, review, or approval of the manuscript.